Stay updated with breaking news from Nahum ferera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer...
NES ZIONA, Israel, Feb. 22, 2022 /PRNewswire/ -- EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer
/PRNewswire/ -- EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer...
EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema Font : A-A+ EndoArt® previously received Innovative Device Status by the Chinese NMPA, and Breakthrough Device Designation from the US Food and Drug Administration TEL AVIV, Israel, June 8, 2021 /PRNewswire/ -- EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announced today that it has received CE Mark for its EndoArt®, after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. The CE Mark serves as approval by the European Union (EU) to commercialize EndoArt®, the world's first and only synthetic implant, which replaces the human endothelium that the human body can never regenerate. The current standard of care involves corneal transplantation of human tissue. This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue. Last month, the EndoArt® became the only ophthalmic device in the world to receive both China's Innovative Device Status and the Breakthrough Device Designation from the U.S. Food and Drug Administration.
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt In China TEL-AVIV, Israel, April 7, 2021 /PRNewswire/ -- EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announces today that EndoArt was granted the Innovative Device Status by China's Center for Medical Device Evaluation, the arm of the National Medical Products Administration (NMPA). Following the announcement, the EndoArt became the only ophthalmic device in the world to receive both China's Innovative Device Status and the Breakthrough Device Designation from the U.S. Food and Drug Administration. The EndoArt is the world's first synthetic implant that enables doctors to treat chronic corneal edema, the main reason for the world's most common organ transplant, with a minimally invasive surgery that erodes the use of human tissue.The EndoArt is designed to replace dysfunctional endothelium in patients awaiting human donor tissue as first-line treatment or patients where the human tissue, which is the current standard of care. A nonfunctioning endothelium results in excess fluid flowing into the cornea, resulting in severe vision loss.
Israeli cornea treatment co EyeYon raises $25m The Israeli company will use the capital to expand clinical trials to treat corneal endema. Israeli medical device company EyeYon Medical EyeYon Medical today announced the completion of a $25 million Series C financing round, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund, together with Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund. The latest round brings the total amount of capital raised by the company to $36 million. EyeYon Medical, which was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera, and Dr. Arie Marcovich, develops advanced technology to treat acute ophthalmic problems.
EyeYon Medical Raises $25 million in Series C to Transform Corneal Care USA - English News provided by Share this article Share this article TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- EyeYon Medical announced today the completion of a $25 million in a Series C funding, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund. Other participants in the round include Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund. EyeYon Medical was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera MD, and Dr. Arie Marcovich, MD., and develops advanced technology to treat acute problems in the ophthalmic world. The latest round brings the total amount of capital raised by the company to $36 million.
Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $25 Million Financing for EyeYon Medical’s EndoArt® Clinical Trials Across Three Continents March 15, 2021 13:05 ET | Source: Quark Venture LP Quark Venture LP Vancouver, British Columbia, CANADA VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities participated in the $25 million financing of EyeYon Medical, to advance its EndoArt ® clinical trials. This investment, made through the Global Health Sciences (GHS) fund, was led by a global ophthalmology industry leader and CRCP alongside new and existing shareholders BPC, Diamond BioFund, Rimonci, Pontifax and Triventures. Quark Venture’s investment in EyeYon Medical will enable the corneal healing solutions provider to accelerate its EndoArt
Israeli startup EyeYon Medical completes $25M Series C round mobihealthnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobihealthnews.com Daily Mail and Mail on Sunday newspapers.